Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma

Open access
Durbin, Adam D., Wang, Tingjian, Wimalasena, Virangika K., Zimmerman, Mark W., Li, Deyao, Dharia, Neekesh V., Mariani, Luca, Shendy, Noha A.M., Nance, Stephanie, Patel, Anand G., Shao, Ying, Mundada, Maya, Maxham, Lily, Park, Paul M.C., Sigua, Logan H., Morita, Ken, Conway, Amy Saur, Robichaud, Amanda L., Perez-Atayde, Antonio R., Bikowitz, Melissa J., Quinn, Taylor R., Wiest, Olaf, Easton, John, Schönbrunn, Ernst, Bulyk, Martha L., Abraham, Brian J., Stegmaier, Kimberly, Look, A. Thomas, Qi, Jun·2022·Cancer Discovery

Abstract

Gene expression is regulated by promoters and enhancers marked by histone H3 lysine 27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HAT) EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depends on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2β, a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeting chimera (PROTAC) compound termed “JQAD1” that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid NB apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Furthermore, JQAD1 activity is critically determined by cereblon (CRBN) expression across NB cells. Significance: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2β. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its activity in NB. JQAD1 has limited toxicity to untransformed cells and is effective in vivo in a CRBN-dependent manner. This article is highlighted in the In This Issue feature, p. 587

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0385

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 162

Metadata

Authors
Durbin, A. D., Wang, T., Wimalasena, V. K., Zimmerman, M. W., Li, D., Dharia, N. V., Mariani, L., Shendy, N. A. M., Nance, S., Patel, A. G., Shao, Y., Mundada, M., Maxham, L., Park, P. M. C., Sigua, L. H., Morita, K., Conway, A. S., Robichaud, A. L., Perez-Atayde, A. R., Bikowitz, M. J., Quinn, T. R., Wiest, O., Easton, J., Schönbrunn, E., Bulyk, M. L., Abraham, B. J., Stegmaier, K., Look, A. T., & Qi, J.
Venue
Cancer Discovery
Published
2022-03-01
Volume
12
Issue
3
Pages
730-751
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3211820355
Cited by
162
References
20
FWCI
10.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0385
The paper
Durbin, A. D., Wang, T., Wimalasena, V. K., Zimmerman, M. W., Li, D., Dharia, N. V., Mariani, L., Shendy, N. A. M., Nance, S., Patel, A. G., Shao, Y., Mundada, M., Maxham, L., Park, P. M. C., Sigua, L. H., Morita, K., Conway, A. S., Robichaud, A. L., Perez-Atayde, A. R., . . . Qi, J. (2022). EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0385

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.